Jan 12, 2021 / 07:50PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Great. Good afternoon, everyone. My name is Jess Fye. I'm one of the senior biotech analysts at JPMorgan, and we're continuing the 2021 Healthcare Conference today with Aprea. I'm joined by the company's CEO, Chris Schade. (Operator Instructions)
So with that out of the way, let me turn it over to Chris.
Christian S. Schade - Aprea Therapeutics, Inc. - President, CEO & Chairman
Thanks, Jess, and happy new year. And on behalf of Aprea, I'd like to thank everyone for attending this afternoon and also to thank JPMorgan for the opportunity to present today.
If we move to Slide 2. Before beginning, I'd like to call everyone's attention to our forward-looking statements and refer you to our filings with the SEC, which explains the risks associated with our business.
Now moving forward to Slide 3. Aprea is the leader in developing novel anticancer therapeutics targeting the tumor suppressor protein, p53. Over the years, we've developed a wealth of preclinical
Aprea Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers